Norepinephrine News and Research

RSS

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

Duloxetine drug alleviates pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.

3 Apr 2013

Research findings shed light on how neurons translate sensory input into actions

New research by scientists at the University of Massachusetts Medical School shows at the single cell level how an external stimulus sets off a molecular chain reaction in the transparent roundworm C. elegans, a process in which a single neurotransmitter coordinates and times two separate actions.

3 Apr 2013

Promising studies for Parkinson's to be presented at 65th AAN meeting

Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are not well-controlled by their main drugs.

15 Mar 2013

Antipsychotic drugs associated with increased risk of stroke in the elderly

Antipsychotic administration in the elderly is associated with an increased risk for cerebrovascular accident, more commonly known as stroke; a new study published in Biological Psychiatry provides additional insight into this important relationship.

12 Mar 2013

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Disulfiram was the first medication approved for the treatment of alcoholism over 50 years ago. It works, at least in part, by preventing the metabolism of an alcohol by-product, acetaldehyde. High levels of acetaldehyde in the body quickly cause unpleasant symptoms, including nausea, vomiting, headache, and accelerated heart rate. Thus, disulfiram provides a very strong incentive to avoid drinking.

1 Feb 2013

ADRB receptors play a direct role in Src activation by PKA-mediated mechanism

Scientists at The University of Texas MD Anderson Cancer Center have discovered the signaling pathway whereby a master regulator of cancer cell proteins - known as Src - leads to ovarian cancer progression when exposed to stress hormones. The researchers report in the current issue of Nature Communications that beta blocker drugs mitigate this effect and reduce cancer deaths by an average of 17 percent.

30 Jan 2013

Fifteen established scientists to receive NARSAD Distinguished Investigator Grants

The Brain & Behavior Research Foundation (formerly NARSAD, the National Alliance for Research on Schizophrenia and Depression) announced the latest recipients of its highly competitive NARSAD Distinguished Investigator Grants.

16 Jan 2013

Beta blocker use linked to NSCLC patient survival

Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.

14 Jan 2013

Antidepressants in normal dosage may positively impact mood and seizure frequency

Epilepsy and depression are common co-morbidities. Concern for the potential of certain antidepressants to induce seizures has led to under-treating depression and anxiety disorders in epilepsy patients. Research presented today at the 66th American Epilepsy Society meeting suggests that antidepressants in normal dosage may have a positive impact on both mood and seizure frequency.

4 Dec 2012

Short instance of moderate exercise improves memories in older adults with MCI

A short burst of moderate exercise enhances the consolidation of memories in both healthy older adults and those with mild cognitive impairment, scientists with UC Irvine's Center for the Neurobiology of Learning & Memory have discovered.

28 Nov 2012

Communications down in anesthetized brain

Two studies indicate that inhaled anesthetics disrupt communication between distant cortical areas before directly activating sleep-inducing neuronal circuitry.

8 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

Renal denervation improves quality of life in hypertension

Renal denervation in patients with treatment-resistant hypertension results in a significantly improved quality of life, a study suggests.

22 Oct 2012

Exercise is the first step to protect against negative impacts of stress

Any time life hands us a stressful situation, we have a decision to make: will we handle it with grace, or let it pile up on everything else? For women, stress sometimes feels like a never-ending occurrence, and University of Alabama at Birmingham experts say that, left unmanaged, stress can lead to health problems. But it can easily be curtailed.

20 Oct 2012

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

Simple test confirms correct catheter placement

Injecting sodium bicarbonate into a peripheral intravenous catheter is a straightforward means of testing its placement and patency in mechanically ventilated children, say researchers.

10 Oct 2012

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Researchers now add electronic sensors to tissue scaffolds

To control the three-dimensional shape of engineered tissue, researchers grow cells on tiny, sponge-like scaffolds. These devices can be implanted into patients or used in the lab to study tissue responses to potential drugs.

28 Aug 2012

Spinal cord stimulation could become novel treatment option for heart failure

Spinal cord stimulation improves heart function and could become a novel treatment option for heart failure, according to research presented at the ESC Congress 2012 today, August 25, by Professor Hung-Fat Tse from Hong Kong.